US 10,376,544 B2
Pluripotent stem cell that induces repair and regeneration after myocardial infarction
Masanori Yoshida, Akita (JP); Shinya Minatoguchi, Gifu (JP); and Mari Dezawa, Miyagi (JP)
Assigned to CLIO, INC., Akita (JP); GIFU UNIVERSITY, Gifu (JP); and TOHOKU UNIVERSITY, Miyagi (JP)
Filed by CLIO, INC., Akita (JP); GIFU UNIVERSITY, Gifu (JP); and TOHOKU UNIVERSITY, Miyagi (JP)
Filed on Nov. 3, 2017, as Appl. No. 15/802,899.
Application 15/802,899 is a continuation of application No. 14/421,754, granted, now 9,844,570, previously published as PCT/JP2013/071981, filed on Aug. 15, 2013.
Claims priority of application No. 2012-181029 (JP), filed on Aug. 17, 2012; and application No. PCT/JP2013/054049 (WO), filed on Feb. 19, 2013.
Prior Publication US 2018/0050067 A1, Feb. 22, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A01K 67/00 (2006.01); A61K 35/28 (2015.01); C12N 5/074 (2010.01)
CPC A61K 35/28 (2013.01) [C12N 5/0607 (2013.01)] 14 Claims
 
1. A method of treating myocardial infarction in a subject in need thereof, the method comprising: administering to said subject a cell preparation comprising isolated pluripotent stem cells positive for SSEA-3, wherein the pluripotent stem cells are isolated from a mesenchymal cell population obtained from mesenchymal tissue or cultured mesenchymal cells, wherein said pluripotent stem cells are isolated by subjecting said mesenchymal cell population to external stress stimulation or cell sorting, to thereby treat the myocardial infarction, and wherein the pluripotent stem cells have a plurality of properties comprising: (i) CD105-positivity; (ii) low or absent telomerase activity; (iii) ability to differentiated into embryonic endoderm, ectoderm, and mesoderm germ layers; (iv) absence of neoplastic proliferation; and (v) ability to self-renew.